Background: The knowledge about the natural history of stroke in Chagas disease is incomplete. Methods: Vascular risk factors and stroke subtypes of asymptomatic Trypanosoma cruzi-infected patients with no clinical evidence of heart failure were assessed. They were compared with chronic chagasic cardiomyopathy patients who suffered a stroke and with a control group of 60 T. cruzi-noninfected stroke patients. Eighty-six consecutive chagasic stroke patients (mean age: 57.4 years; 64% females) were studied. Results: 38.4% of chagasic stroke patients had asymptomatic T. cruzi infection. Smoking was more frequent in asymptomatic chagasic stroke patients (21.2 vs. 5.7%; p = 0.04). Prevalence of hypertension, diabetes and prior stroke was similar in both groups. Small-vessel infarction (15.6 vs. 3.8%) and large-vessel atherosclerosis (9.4 vs. 3.8%) were significantly more frequent in asymptomatic than in symptomatic T. cruzi- infected stroke patients (p = 0.001). Nevertheless, their frequency was even higher in T. cruzi-noninfected stroke patients (36.7 and 13.3%, respectively). Apical aneurysm (27.3%), left atrial dilatation (12.1%), left ventricle hypokinesia (9.4%) and right bundle branch block (36.4%) were also detected in asymptomatic T. cruzi-infected stroke patients. Conclusions: Ischemic stroke may be the first manifestation of Chagas disease in asymptomatic patients with mild left ventricle dysfunction. Other noncardioembolic stroke subtypes can occur in asymptomatic T. cruzi-infected patients.

Keywords:
American trypanosomiasis, Chagas disease, Trypanosoma cruzi, Stroke
1.
Carod-Artal FJ: Stroke: a neglected complication of American trypanosomiasis (Chagas’ disease). Trans R Soc Trop Med Hyg 2007;101:1075–1080.
2.
Bern C, Montgomery SP: An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009;49:e52–e54.
3.
Muñoz J, Gómez i Prat J, Gállego M, Gimeno F, Treviño B, López-Chejade P, Ribera O, Molina L, Sanz S, Pinazo MJ, Riera C, Posada EJ, Sanz G, Portús M, Gascon J: Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop 2009;111:51–55.
4.
Milei J, Guerri-Guttenberg RA, Grana DR, Storino R: Prognostic impact of Chagas disease in the United States. Am Heart J 2009;157:22–29.
5.
Carod-Artal FJ, Ribeiro L da S, Vargas AP: Awareness of stroke risk in chagasic stroke patients. J Neurol Sci 2007;263:35–39.
6.
Carod-Artal FJ, Gascón J: Chagas disease and stroke. Lancet Neurol 2010;9:533–542.
7.
Moncayo A, Silveira AC: Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009;104(suppl 1):17–30.
8.
Carod Artal FJ, Vargas AP, Melo M, Horan TA: American trypanosomiasis (Chagas’ disease): an unrecognized cause of stroke. J Neurol Neurosurg Psychiatry 2003;74:516–518.
9.
Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG: Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 2005;36:965–970.
10.
Carvalho da Paixão L, Pinho Ribeiro AL, Valacio RA, Teixeira AL: Chagas disease. Independent risk factor for stroke. Stroke 2009;40:3691–3694.
11.
Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB: The Stroke Data Bank: design, methods, and baseline characteristics. Stroke 1988;19:547–554.
12.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993;24:35–41.
13.
Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG: New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 2009;27:502–508.
14.
Chagas C: Nova tripanozomiase humana: estudos sob a morfologia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., s. sp. agente etiológico de nova entidade mórbida no homem. Mem Inst Oswaldo Cruz 1909;1:159–218.
15.
Prata A: Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001;1:92–100.
16.
Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV: Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109–1123.
17.
Oliveira-Filho J, Viana LC, Vieira de Melo RM, Faiçal F, Torreão JA, Villar FA, Reis FJ: Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas disease cohort. Stroke 2005;36:2015–2017.
18.
Lima-Costa MF, Castro-Costa E, Uchóa E, Firmo J, Ribeiro AL, Ferri CP, Prince M: A population-based study of the association between Trypanosoma cruzi infection and cognitive impairment in old age (The Bambuí Study). Neuroepidemiology 2009;32:122–128.
19.
Pereira AB, Alvarenga H, Pereira RS Jr, Barbosa MT: Stroke prevalence among the elderly in Vassouras,Rio de Janeiro State, Brazil, according to data from the Family Health Program. Cad Saude Publica 2009;25:1929–1936.
20.
Rassi Jr A, Dias JCP, Marin-Neto JA: Challenges and opportunities for primary, secondary and tertiary prevention of Chagas’ disease. Heart 2009;95:524–534.
21.
Bestetti R: Stroke in a hospital-derived cohort of patients with chronic Chagas’ disease. Acta Cardiol 2000;55:33–38.
22.
Nunes MC, Barbosa MM, Ribeiro AL, Barbosa FB, Rocha MO: Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J Neurol Sci 2009;278:96–101.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.